Altor BioScience Corporation Awarded $3 MM SBIR Phase II Competing Renewal Grant by NHBLI

Published: May 23, 2011

Altor BioScience Corporation announced today that the National Heart Lung and Blood Institute (NHLBI) has awarded Altor a Small Business Innovation Research (SBIR) Phase II Competing Renewal Grant. The award of over $3.18 MM over three years will support Altor’s efforts to complete a second Phase 2 clinical trial using ALT-836, an antibody-based tissue factor (TF) antagonist, as a therapy to treat patients with infection-induced acute lung injury/acute respiratory distress syndrome (ALI/ARDS). Patient enrollment of this 90-patient, multi-center, randomized, placebo-controlled trial using a multi-dose regimen of ALT-836 has been initiated. This trial follows a recently completed 60-patient, multi-center, randomized, placebo-controlled trial with a single-dose of ALT-836, which was also supported by a Phase II SBIR grant from NHLBI. The results of that recently completed Phase 2 trial suggest that a single dose of ALT-836 provides benefit to patients with ALI/ARDS without additional risks of bleeding complications, a major safety concern associated with this kind of therapy.

Back to news